piracetam has been researched along with Brain Ischemia in 52 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effects of piracetam in acute, presumed ischaemic stroke." | 8.88 | Piracetam for acute ischaemic stroke. ( Cantisani, TA; Celani, MG; Ricci, S; Righetti, E, 2012) |
| " The use of AEDs as a possible neuroprotective strategy in brain ischemia is receiving increasing attention and the antiepileptic drug levetiracetam, a 2S-(2-oxo-1-pyrrolidiny1) butanamide, belonging to the pyrrolidone family, could have a crucial role in regulation of epileptogenesis and neuroprotection." | 8.87 | Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy. ( Belcastro, V; Pierguidi, L; Tambasco, N, 2011) |
| "There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials." | 8.83 | Piracetam for acute ischaemic stroke. ( Cantisani, AT; Celani, MG; Ricci, S; Righetti, E, 2006) |
| "There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials." | 8.81 | Piracetam for acute ischaemic stroke. ( Cantisani, AT; Celani, MG; Ricci, S; Righetti, E, 2002) |
| "The objective of this review was to assess the effects of piracetam in acute presumed ischaemic stroke." | 8.80 | Piracetam for acute ischaemic stroke. ( Cantisani, AT; Celani, MG; Ricci, S; Righetti, E, 2000) |
| "The purpose of this study is to explore the neuroprotection mechanism of levetiracetam (LEV) with acute focal cerebral ischemia-reperfusion (I/P) mouse." | 7.83 | Levetiracetam Prevents Perforin Mediated Neuronal Injury Induced by Acute Cerebral Ischemia Reperfusion. ( Bao, H; Hao, J; Li, G; Li, Y; Wang, X; Xu, X; Zhang, Y; Zuo, L, 2016) |
| "Current guidelines recommend against the use of phenytoin following aneurysmal subarachnoid hemorrhage (aSAH) but consider other anticonvulsants, such as levetiracetam, acceptable." | 7.80 | Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage. ( Fletcher, JJ; Karamchandani, RR; Pandey, AS; Rajajee, V, 2014) |
| " Plasma concentrations (pc), interactions between drugs in the ICU context, adverse effects and seizure occurrences were observed and recorded." | 5.37 | Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage. ( Bjeljac, M; Keller, E; Mink, S; Muroi, C; Seule, M, 2011) |
| "Levetiracetam (LEV) is a new antiepileptic drug with a promising preclinical profile involving both anticonvulsant and antiepileptogenic effects in kindling models." | 5.31 | Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. ( Hanon, E; Klitgaard, H, 2001) |
| "To assess the effects of piracetam in acute, presumed ischaemic stroke." | 4.88 | Piracetam for acute ischaemic stroke. ( Cantisani, TA; Celani, MG; Ricci, S; Righetti, E, 2012) |
| " The use of AEDs as a possible neuroprotective strategy in brain ischemia is receiving increasing attention and the antiepileptic drug levetiracetam, a 2S-(2-oxo-1-pyrrolidiny1) butanamide, belonging to the pyrrolidone family, could have a crucial role in regulation of epileptogenesis and neuroprotection." | 4.87 | Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy. ( Belcastro, V; Pierguidi, L; Tambasco, N, 2011) |
| "There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials." | 4.83 | Piracetam for acute ischaemic stroke. ( Cantisani, AT; Celani, MG; Ricci, S; Righetti, E, 2006) |
| "There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials." | 4.81 | Piracetam for acute ischaemic stroke. ( Cantisani, AT; Celani, MG; Ricci, S; Righetti, E, 2002) |
| "The objective of this review was to assess the effects of piracetam in acute presumed ischaemic stroke." | 4.80 | Piracetam for acute ischaemic stroke. ( Cantisani, AT; Celani, MG; Ricci, S; Righetti, E, 2000) |
| "The purpose of this study is to explore the neuroprotection mechanism of levetiracetam (LEV) with acute focal cerebral ischemia-reperfusion (I/P) mouse." | 3.83 | Levetiracetam Prevents Perforin Mediated Neuronal Injury Induced by Acute Cerebral Ischemia Reperfusion. ( Bao, H; Hao, J; Li, G; Li, Y; Wang, X; Xu, X; Zhang, Y; Zuo, L, 2016) |
| "Current guidelines recommend against the use of phenytoin following aneurysmal subarachnoid hemorrhage (aSAH) but consider other anticonvulsants, such as levetiracetam, acceptable." | 3.80 | Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage. ( Fletcher, JJ; Karamchandani, RR; Pandey, AS; Rajajee, V, 2014) |
| "The aim of the present work was to compare the morphological changes occurring at the focus of experimental ischemic stroke treated with agents of the neurotrophic group (alpha-GPC, cerebrolysin), an agent with nootropic properties (piracetam), and a mixed-action agent (vinpocetine)." | 3.74 | Changes at the focus of experimental ischemic stroke treated with neuroprotective agents. ( Gaikova, ON; Onishchenko, LS; Yanishevskii, SN, 2008) |
| "The purpose of this study was to compare the morphological changes in the focus of ischemic stroke under the influence of the drugs of neurotrophic group (alpha-GPC, cerebrolysin), drugs possessing the nootropic properties (piracetam) and those with combined effect (vinpocetin)." | 3.73 | [Changes in the focus of experimental ischemic stroke under the influence of neuroprotective drugs]. ( Gaĭkova, ON; Ianishevskiĭ, SN; Onishchenko, LS, 2006) |
| "The protective efficacy of pentoxiphylline, piracetam, and dihydroergotoxine against abrupt hypoxia was tested in a model of acute reversible respiratory failure, where repeated apnoeic attacks were induced by inhalation in repeated hypoxic exposures was reduced in control as well as in dihydroergotoxine-treated animals, it was increased after pentoxiphylline, and was not changed after piracetam." | 3.67 | Anti-hypoxic potency of cerebroprotective drugs studied in a model of acute reversible respiratory failure. ( Nistiarová, A; Tkácová, R; Tomori, Z, 1989) |
| "The data from studies presenting cerebrovascular diseases associated with SARS-Cov-2, which constituted 0." | 1.72 | Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies? ( Ates, O; Dogan, M; Ersoz, E; Hacioglu Kasim, FB; Karaarslan, N; Ozbek, H; Yilmaz, I, 2022) |
| "Focal cerebral ischemia was induced by middle cerebral artery occlusion for 2 h in male Wistar rats followed by reperfusion." | 1.48 | Pharmacokinetic Study of Piracetam in Focal Cerebral Ischemic Rats. ( Dash, D; Krishnamurthy, S; Paliwal, P, 2018) |
| "Perinatal arterial stroke is the most frequent form of cerebral infarction in children." | 1.46 | Different response to antiepileptic drugs according to the type of epileptic events in a neonatal ischemia-reperfusion model. ( Auvin, S; Baud, O; Bonnin, P; Charriaut-Marlangue, C; Dupuis, N; Enderlin, J; Leger, PL; Morin, L; Perrotte, G, 2017) |
| "Sixty-seven patients with chronic cerebral ischemia (TE stage II),48 women and 19 men, mean age 48." | 1.43 | [The system stress-limiting action of mexidol in chronic cerebral ischemia]. ( Antipenko, EA; Derugina, AV; Gustov, AV, 2016) |
| "Piracetam treatment improved neurological and histopathological alterations, reduced water content and infarct size, but failed to restore/prevent the impaired endogenous defense functions significantly." | 1.39 | Amelioration of cognitive, motor and endogenous defense functions with silymarin, piracetam and protocatechuic acid in the cerebral global ischemic rat model. ( Bafna, PA; Muley, MM; Naik, SR; Patil, RR; Thakare, VN, 2013) |
| " Plasma concentrations (pc), interactions between drugs in the ICU context, adverse effects and seizure occurrences were observed and recorded." | 1.37 | Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage. ( Bjeljac, M; Keller, E; Mink, S; Muroi, C; Seule, M, 2011) |
| "Stroke is associated with elevation of several proinflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-8 that are correlated with central nervous system (CNS) injury." | 1.34 | TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. ( Al-Bahrani, A; Bakhiet, M; Shaath, H; Taha, S, 2007) |
| "Levetiracetam (LEV) is a new antiepileptic drug with a promising preclinical profile involving both anticonvulsant and antiepileptogenic effects in kindling models." | 1.31 | Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. ( Hanon, E; Klitgaard, H, 2001) |
| "Authors report a case of focal action myoclonus due to a localized hemispheric lesion." | 1.29 | [Myoclonus of focal action and localized hemispheric lesion. A polygraphic and pharmacological study]. ( Bartolomei, F; Bureau, M; Genton, P; Paglia, G; Roger, J, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (11.54) | 18.7374 |
| 1990's | 8 (15.38) | 18.2507 |
| 2000's | 20 (38.46) | 29.6817 |
| 2010's | 17 (32.69) | 24.3611 |
| 2020's | 1 (1.92) | 2.80 |
| Authors | Studies |
|---|---|
| Ates, O | 1 |
| Yilmaz, I | 1 |
| Karaarslan, N | 1 |
| Ersoz, E | 1 |
| Hacioglu Kasim, FB | 1 |
| Dogan, M | 1 |
| Ozbek, H | 1 |
| Paliwal, P | 1 |
| Dash, D | 1 |
| Krishnamurthy, S | 1 |
| Muley, MM | 2 |
| Thakare, VN | 2 |
| Patil, RR | 2 |
| Bafna, PA | 1 |
| Naik, SR | 2 |
| Karamchandani, RR | 1 |
| Fletcher, JJ | 1 |
| Pandey, AS | 1 |
| Rajajee, V | 1 |
| Fedin, AI | 1 |
| Solov'eva, ÉI | 1 |
| Mironova, OP | 1 |
| Fedotova, AV | 1 |
| Zhang, Y | 1 |
| Li, Y | 1 |
| Zuo, L | 1 |
| Bao, H | 1 |
| Xu, X | 1 |
| Hao, J | 1 |
| Wang, X | 1 |
| Li, G | 1 |
| Konoplya, AI | 1 |
| Laskov, VB | 1 |
| Shul'ginova, AA | 1 |
| Antipenko, EA | 1 |
| Derugina, AV | 1 |
| Gustov, AV | 1 |
| Yasnetsov, VV | 2 |
| Tsublova, EG | 1 |
| Skachilova, SY | 1 |
| Karsanova, SK | 1 |
| Ivanov, YV | 1 |
| Morin, L | 1 |
| Enderlin, J | 1 |
| Leger, PL | 1 |
| Perrotte, G | 1 |
| Bonnin, P | 1 |
| Dupuis, N | 1 |
| Baud, O | 1 |
| Charriaut-Marlangue, C | 1 |
| Auvin, S | 1 |
| Arabkhanova, MA | 1 |
| Pyshkina, LI | 1 |
| Kabanov, AA | 2 |
| Kolesnikova, TI | 1 |
| Iasamanova, AN | 1 |
| Martynov, MIu | 1 |
| Gusev, EI | 3 |
| Ivanova, NE | 1 |
| Panuntsev, VS | 1 |
| Kalinskiĭ, PP | 1 |
| Nazarov, VV | 1 |
| Samarets, NA | 1 |
| Ulitina, MN | 1 |
| Derev'yannykh, EA | 1 |
| Bel'skaya, GN | 1 |
| Knoll, EA | 1 |
| Krylova, LG | 1 |
| Popov, DV | 1 |
| Belcastro, V | 2 |
| Costa, C | 1 |
| Galletti, F | 1 |
| Autuori, A | 1 |
| Pierguidi, L | 2 |
| Pisani, F | 1 |
| Calabresi, P | 1 |
| Parnetti, L | 1 |
| Kuznetsov, AN | 1 |
| Daminov, VD | 1 |
| Stroganova, IM | 1 |
| Kiparisov, MA | 1 |
| Tambasco, N | 1 |
| Vorob'eva, OV | 1 |
| Tamarova, ES | 1 |
| Kamchatnov, PR | 1 |
| Zaĭtsev, KA | 1 |
| Denisov, DB | 1 |
| Mink, S | 1 |
| Muroi, C | 1 |
| Seule, M | 1 |
| Bjeljac, M | 1 |
| Keller, E | 1 |
| Kshirsagar, AD | 1 |
| Ricci, S | 4 |
| Celani, MG | 4 |
| Cantisani, TA | 1 |
| Righetti, E | 4 |
| Chukanova, EI | 1 |
| Khodzhamzharov, BÉ | 1 |
| Chukanova, AS | 1 |
| Cantisani, AT | 3 |
| Xerri, C | 1 |
| Zennou-Azogui, Y | 1 |
| Boĭko, AN | 1 |
| Es'kina, TA | 1 |
| Sheliakina, LA | 1 |
| Shchukin, AI | 1 |
| Batysheva, TT | 1 |
| Artemova, IIu | 1 |
| Vdovichenko, TV | 1 |
| Volovets, SA | 1 |
| Ganzhula, PA | 1 |
| Krylova, IB | 1 |
| Bulion, VV | 1 |
| Gavrovskaya, LK | 1 |
| Selina, EN | 1 |
| Kuznetzova, NN | 1 |
| Sapronov, NS | 1 |
| Al-Bahrani, A | 1 |
| Taha, S | 1 |
| Shaath, H | 1 |
| Bakhiet, M | 1 |
| Onishchenko, LS | 2 |
| Gaĭkova, ON | 2 |
| Ianishevskiĭ, SN | 1 |
| Striano, P | 1 |
| Elefante, A | 1 |
| Coppola, A | 1 |
| Tortora, F | 1 |
| Zara, F | 1 |
| Minetti, C | 1 |
| Striano, S | 1 |
| Chan, S | 1 |
| Ros, S | 1 |
| You, KY | 1 |
| Nhem, S | 1 |
| Salle, JY | 1 |
| Dudognon, P | 1 |
| Daviet, JC | 1 |
| Yanishevskii, SN | 1 |
| Skorokhodov, AP | 1 |
| Dudina, AA | 1 |
| Kolesnikova, EA | 1 |
| Koron, AE | 1 |
| Kobantsev, IuA | 1 |
| Sedova, AA | 1 |
| Ivanova, IA | 1 |
| Bobkov, IuG | 1 |
| Bogolepov, NN | 1 |
| Burd, GS | 3 |
| Buklina, SB | 2 |
| Bartolomei, F | 1 |
| Bureau, M | 1 |
| Paglia, G | 1 |
| Genton, P | 1 |
| Roger, J | 1 |
| Klimenko, VN | 1 |
| Belenichev, IF | 1 |
| Bashkin, IN | 1 |
| Shavrin, VA | 1 |
| Vizir, VA | 1 |
| Guĭtur, MM | 1 |
| Raevskiĭ, KS | 1 |
| Romanova, GA | 1 |
| Kudrin, VS | 1 |
| Malikova, LA | 1 |
| De Deyn, PP | 1 |
| Reuck, JD | 1 |
| Deberdt, W | 1 |
| Vlietinck, R | 1 |
| Orgogozo, JM | 1 |
| Gekht, AB | 2 |
| Skvortsova, VI | 1 |
| Selikhova, MV | 1 |
| Pavlov, NA | 1 |
| Bolotov, DA | 1 |
| Beliakov, VV | 1 |
| Vanichkin, AV | 1 |
| Konstantinova, MV | 1 |
| Bogolepova, AN | 1 |
| Kozubski, W | 1 |
| Andreeva, NA | 1 |
| Stel'mashuk, EV | 1 |
| Isaev, NK | 1 |
| Ostrovskaya, RU | 1 |
| Gudasheva, TA | 1 |
| Viktorov, IV | 1 |
| Hanon, E | 1 |
| Klitgaard, H | 1 |
| Sinforiani, E | 1 |
| Iannuccelli, M | 1 |
| Mauri, M | 1 |
| Costa, A | 1 |
| Merlo, P | 1 |
| Bono, G | 1 |
| Nappi, G | 1 |
| Herrschaft, H | 1 |
| Tkácová, R | 1 |
| Tomori, Z | 1 |
| Nistiarová, A | 1 |
| Berga, P | 1 |
| Beckett, PR | 1 |
| Roberts, DJ | 1 |
| Llenas, J | 1 |
| Massingham, R | 1 |
| Sato, M | 1 |
| Heiss, WD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage[NCT01935908] | Phase 4 | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to no funding) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for piracetam and Brain Ischemia
| Article | Year |
|---|---|
Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy.
Topics: Animals; Anticonvulsants; Brain Ischemia; Clinical Trials as Topic; Disease Models, Animal; Epilepsy | 2011 |
Piracetam for acute ischaemic stroke.
Topics: Acute Disease; Brain Ischemia; Fibrinolytic Agents; Humans; Neuroprotective Agents; Piracetam; Rando | 2012 |
[Current possibilities of the correction of oxidative stress in acute brain ischaemia].
Topics: Antioxidants; Brain Ischemia; Humans; Oxidative Stress; Pentoxifylline; Piracetam; Reactive Oxygen S | 2012 |
Piracetam for acute ischaemic stroke.
Topics: Acute Disease; Brain Ischemia; Humans; Neuroprotective Agents; Piracetam; Stroke | 2002 |
Piracetam for acute ischaemic stroke.
Topics: Acute Disease; Brain Ischemia; Humans; Neuroprotective Agents; Piracetam; Stroke | 2006 |
Piracetam for acute ischaemic stroke.
Topics: Brain Ischemia; Humans; Neuroprotective Agents; Piracetam; Stroke | 2000 |
8 trials available for piracetam and Brain Ischemia
| Article | Year |
|---|---|
Levetiracetam in newly diagnosed late-onset post-stroke seizures: a prospective observational study.
Topics: Aged; Aged, 80 and over; Aggression; Anticonvulsants; Brain Ischemia; Cardiovascular Agents; Drug In | 2008 |
[Implication of vinpotropile in the treatment of patients with cerebral stroke].
Topics: Adult; Aged; Brain Ischemia; Drug Combinations; Female; Humans; Male; Middle Aged; Piracetam; Vasodi | 2007 |
[Efficacy of vinpotropile in the therapy of initial signs of cerebrovascular pathology].
Topics: Aged; Brain Ischemia; Cognition Disorders; Drug Combinations; Female; Humans; Male; Middle Aged; Moo | 2010 |
[Phezam efficacy in patients with chronic cerebral ischemic disease].
Topics: Aged; Brain; Brain Ischemia; Calcium Channel Blockers; Cerebrovascular Circulation; Chronic Disease; | 2005 |
[Comparative analysis of efficacy of certain neuroprotectors in ischemic stroke].
Topics: Aged; Amino Acids; Brain; Brain Ischemia; Echoencephalography; Female; Follow-Up Studies; Humans; In | 2006 |
Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group.
Topics: Acute Disease; Aged; Aged, 80 and over; Brain Ischemia; Cerebrovascular Disorders; Double-Blind Meth | 1997 |
Porównanie skuteczności piracetamu i dekstranu 40 tys. u chorych w podeszlym wieku z niedokrwiennym udarem mózgu.
Topics: Acute Disease; Aged; Brain; Brain Ischemia; Dextrans; Female; Humans; Male; Middle Aged; Neuroprotec | 1998 |
[The effectiveness of piracetam in acute cerebral ischemia in the human. A clinical controlled double-blind study of piracetam/10% dextran 40 versus 10% dextran 40/placebo].
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Cerebral Infarction; Clinical Trials as Topic; Dextr | 1988 |
38 other studies available for piracetam and Brain Ischemia
| Article | Year |
|---|---|
Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies?
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; COVID-19; Enoxaparin; Humans; Manni | 2022 |
Pharmacokinetic Study of Piracetam in Focal Cerebral Ischemic Rats.
Topics: Administration, Oral; Animals; Brain; Brain Ischemia; Disease Models, Animal; Dose-Response Relation | 2018 |
Amelioration of cognitive, motor and endogenous defense functions with silymarin, piracetam and protocatechuic acid in the cerebral global ischemic rat model.
Topics: Analysis of Variance; Animals; Brain Ischemia; Catalase; Cognition; Glutathione; Histological Techni | 2013 |
Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Brain Ischemia; Female; Follow-Up Stud | 2014 |
[Treatment of asthenic syndrome in patients with chronic brain ischemia: results of the non-interventional observational program TRIUMPH].
Topics: Aged; Aged, 80 and over; Asthenia; Brain Ischemia; Chronic Disease; Female; Humans; Male; Middle Age | 2014 |
Levetiracetam Prevents Perforin Mediated Neuronal Injury Induced by Acute Cerebral Ischemia Reperfusion.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Female; Levetiracetam; Male; Mice, Inbred C57BL; Mice, | 2016 |
[Immune and oxygen disturbances in patients with chronic cerebral ischemia and their correction].
Topics: Adult; Amino Acids; Antioxidants; Brain Ischemia; C-Reactive Protein; Chronic Disease; Complement C1 | 2015 |
[The system stress-limiting action of mexidol in chronic cerebral ischemia].
Topics: Antioxidants; Brain Ischemia; Female; Humans; Male; Middle Aged; Picolines; Piracetam | 2016 |
[STUDYING SOME PHARMACOLOGICAL EFFECTS OF NEW 3-HYDROXYPYRIDINE DERIVATIVE].
Topics: Adamantane; Amnesia; Animals; Animals, Outbred Strains; Anticonvulsants; Benzimidazoles; Brain Ische | 2016 |
Different response to antiepileptic drugs according to the type of epileptic events in a neonatal ischemia-reperfusion model.
Topics: Animals; Animals, Newborn; Anticonvulsants; Brain; Brain Ischemia; Disease Models, Animal; Epilepsy; | 2017 |
[Phezam in combined therapy of ischemic stroke].
Topics: Administration, Oral; Blood Flow Velocity; Brain Ischemia; Cerebral Arteries; Cerebrovascular Circul | 2008 |
[The use of vinpotropile in chronic brain ishemia].
Topics: Adult; Aged; Brain Ischemia; Chronic Disease; Drug Combinations; Female; Humans; Male; Middle Aged; | 2008 |
[Peculiarities of treatment of asthenic syndrome in the acute period of ischemic stroke].
Topics: Acute Disease; Aged; Asthenia; Brain Ischemia; Female; Humans; Male; Middle Aged; Nootropic Agents; | 2008 |
Experience in the use of Actovegin in the treatment of patients with cognitive disorders in the acute period of stroke.
Topics: Aged; Brain Ischemia; Central Nervous System Stimulants; Cerebral Infarction; Cerebrovascular Circul | 2008 |
[Omaron in the restorative treatment of patients with chronic cerebrovascular insufficiency].
Topics: Administration, Oral; Atherosclerosis; Brain Ischemia; Calcium Channel Blockers; Carotid Arteries; C | 2010 |
[The use of vinpotropile in brain ischemia].
Topics: Adult; Aged; Brain Ischemia; Combined Modality Therapy; Drug Combinations; Humans; Middle Aged; Pira | 2011 |
Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage.
Topics: Administration, Oral; Aged; Aneurysm, Ruptured; Anti-Bacterial Agents; Anticonvulsants; Biological A | 2011 |
Silymarin improves the behavioural, biochemical and histoarchitecture alterations in focal ischemic rats: a comparative evaluation with piracetam and protocatachuic acid.
Topics: Animals; Behavior, Animal; Brain Ischemia; Catalase; Glutathione; Hydroxybenzoates; Lipid Peroxidati | 2012 |
Influence of the postlesion environment and chronic piracetam treatment on the organization of the somatotopic map in the rat primary somatosensory cortex after focal cortical injury.
Topics: Afferent Pathways; Animals; Brain Injuries; Brain Ischemia; Brain Mapping; Cell Death; Cerebral Infa | 2003 |
Neuroprotective effect of a new taurinamide derivative--Taurepar.
Topics: Amides; Amino Acids; Animals; Brain Ischemia; Male; Neuroprotective Agents; Piracetam; Rats; Rats, W | 2006 |
TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents.
Topics: Acute Disease; Adult; Aged; Aspirin; Brain Ischemia; Cells, Cultured; Clopidogrel; Dipyridamole; Fem | 2007 |
[Changes in the focus of experimental ischemic stroke under the influence of neuroprotective drugs].
Topics: Amino Acids; Animals; Brain; Brain Ischemia; Glycerylphosphorylcholine; Male; Neuroprotective Agents | 2006 |
Dramatic response to levetiracetam in post-ischaemic Holmes' tremor.
Topics: Brain Ischemia; Cerebral Hemorrhage; Humans; Infarction; Levetiracetam; Male; Middle Aged; Nootropic | 2007 |
[The management of stroke in Phnom Penh, Cambodia].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Calcium Channe | 2007 |
Changes at the focus of experimental ischemic stroke treated with neuroprotective agents.
Topics: Amino Acids; Animals; Brain; Brain Ischemia; Glycerylphosphorylcholine; Male; Neuroprotective Agents | 2008 |
[Comparative study of several preparations in different models of cerebral hypoxia].
Topics: Animals; Asphyxia; Brain Ischemia; Disease Models, Animal; Drug Evaluation, Preclinical; Electrocard | 1984 |
[Ultrastructural aspects of acute cerebral ischemia during nootropil administration (experimental study)].
Topics: Acute Disease; Animals; Brain Ischemia; Cerebral Cortex; Energy Metabolism; Nerve Degeneration; Nerv | 1983 |
[Myoclonus of focal action and localized hemispheric lesion. A polygraphic and pharmacological study].
Topics: Anticonvulsants; Brain Diseases; Brain Ischemia; Cerebral Cortex; Clonazepam; Electroencephalography | 1995 |
[Pharmacologic protection of brain in surgery of the brachiocephalic arteries].
Topics: Animals; Brachiocephalic Trunk; Brain Ischemia; Carotid Arteries; Constriction; Dogs; Endarterectomy | 1993 |
[Balance of neuromediatory amino acids and impairment of integral brain activity caused by local ischemia of frontal lobe in rats: effects of piracetam and glycine].
Topics: Animals; Avoidance Learning; Brain Ischemia; Frontal Lobe; Glycine; Male; Motor Activity; Neuroprote | 1997 |
[The metabolic therapy of ischemic stroke: the use of nootropil].
Topics: Acute Disease; Brain Ischemia; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Eva | 1997 |
[Nootropil in the treatment of disorders of the higher mental functions in patients with an ischemic stroke].
Topics: Acute Disease; Aged; Brain Ischemia; Combined Modality Therapy; Dominance, Cerebral; Female; Higher | 1997 |
Neuroprotective properties of nootropic dipeptide GVS-111 in in vitro oxygen-glucose deprivation, glutamate toxicity and oxidative stress.
Topics: 2-Amino-5-phosphonovalerate; Animals; Brain Ischemia; Cells, Cultured; Cerebellum; Dipeptides; Gluco | 2000 |
Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia.
Topics: Animals; Anticonvulsants; Arterial Occlusive Diseases; Body Temperature; Brain; Brain Ischemia; Cere | 2001 |
Neuropsychological changes in demented patients treated with acetyl-L-carnitine.
Topics: Acetylcarnitine; Aged; Brain Ischemia; Carnitine; Dementia; Female; Humans; Male; Middle Aged; Pirac | 1990 |
Anti-hypoxic potency of cerebroprotective drugs studied in a model of acute reversible respiratory failure.
Topics: Animals; Brain Ischemia; Cats; Dihydroergotoxine; Disease Models, Animal; Electrocardiography; Hypox | 1989 |
Synergistic interactions between piracetam and dihydroergocristine in some animal models of cerebral hypoxia and ischaemia.
Topics: Anesthesia; Animals; Avoidance Learning; Brain Ischemia; Cerebrovascular Circulation; Dihydroergotox | 1986 |
Effect of piracetam on cerebral blood flow and somatosensory evoked potential during normotension and hypotensive ischemia in cats.
Topics: Animals; Blood Pressure; Brain Ischemia; Cats; Cerebrovascular Circulation; Evoked Potentials, Somat | 1985 |